



CARMAT lists on NYSE Alternext

Paris, 13 July 2010 – NYSE Euronext today announced the admission to NYSE Alternext of CARMAT, a biomedical company pioneering the development of a fully implantable artificial heart.

Founded in 2008, CARMAT aims to meet the challenge of treating late-stage heart failure with a fully implantable artificial heart that is as close as possible to the human heart. The project reflects 15 years of research and successful teamwork between cardiovascular surgeon Alain Carpentier and the EADS group.

The admission of CARMAT (ticker symbol: ALCAR) to NYSE Alternext was by the listing of 2,811,950 existing shares making up its capital, 161,107 new shares resulting from the conversion of convertible bonds (“OCA-2010”) and the exercise of equity warrants (“BSA-LI” and “BSA-OC”), and 827,002 new shares issued as part of a global offering¹, including the partial exercise of the Extension Option.

The admission and issue price of CARMAT shares was set at EUR 18.75 each. The company’s market capitalization on the day of admission amounted to EUR 71.3 million.

“We are proud to accompany CARMAT in this new stage in its growth and to participate in the development of a fully implantable artificial heart, comments Ronald Kent, Group Executive Vice President and Head of International Listings at NYSE Euronext. Going public will enable CARMAT to diversify its financial resources while reinforcing its structure and raising its profile.”

Marcello Conviti, Chief Executive of CARMAT said: *“We are delighted with the success of our share offering, which is one of the biggest on NYSE Alternext since the beginning of the year. Funds raised will enable us to test implants of a completely artificial heart in humans from 2011 on, aiming for a full-scale rollout in 2013.”*

NYSE Alternext today counts 146 listed companies from countries including Belgium, Canada, China, France, Italy, Luxembourg, the Netherlands, Spain, the UK and the US. Together they have raised over EUR 2.3 billion, half of this through secondary issues, and their market capitalization totals EUR 4.4 billion.

¹ A global offering consists of a public offering including a global placement with institutional investors in France and abroad, and an open-price offering.



Press contacts:

NYSE Euronext (Paris): +33 (0)1 49 27 11 33

ALIZE RP:

Caroline Carmagnol – caroline@alizerp.com: +33 (0)6 64 18 99 59

Juliette Vandenbroucq – juliette@alizerp.com: +33 (0)1 42 68 86 41

About CARMAT SAS

CARMAT SAS is an innovative biomedical business financed by Truffle Capital, EADS and Professor Carpentier, with support from Oseo. It was founded on June 30, 2008.

The company aims to produce a fully implantable artificial heart, designed to be as close as possible to the human heart and including both right and left ventricles. The device, which has taken nearly 15 years to develop, makes use of biomaterials and advanced materials and reflects the successful teamwork of cardiovascular surgeon Alain Carpentier and EADS.

About NYSE Euronext

NYSE Euronext (NYX) is a leading global operator of financial markets and provider of innovative trading technologies. The company's exchanges in Europe and the United States trade equities, futures, options, fixed-income and exchange-traded products. With approximately 8,000 listed issues (excluding European Structured Products), NYSE Euronext's equities markets – the New York Stock Exchange, NYSE Euronext, NYSE Amex, NYSE Alternext and NYSE Arca – represent one-third of the world's equities trading, the most liquidity of any global exchange group. NYSE Euronext also operates NYSE Liffe, one of the leading European derivatives businesses and the world's second-largest derivatives business by value of trading. The company offers comprehensive commercial technology, connectivity and market data products and services through NYSE Technologies. NYSE Euronext is in the S&P 500 index, and is the only exchange operator in the S&P 100 index and Fortune 500. For more information, please visit: www.nyx.com